ライフサイエンスコーパス: midodrine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 hypotension may respond to erythropoietin or midodrine.

2 f placebo, the alpha1-adrenoreceptor agonist midodrine (5 to 10 mg), the alpha2-adrenoreceptor agonis

3 e randomized to receive a nonpressor dose of midodrine (5mg) or placebo on day 1 and the opposite on

4 ossover trial to investigate the efficacy of midodrine, a selective alpha-1 adrenergic agonist that d

5 with albumin (TERLI group) and 22 to receive midodrine and octreotide plus albumin (MID/OCT group).

6 albumin is significantly more effective than midodrine and octreotide plus albumin in improving renal

7 tiveness of terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment o

8 n is not available, as in the United States, midodrine and octreotide with albumin are used as an alt

9 The efficacy of Midodrine and Serotonin Uptake Inhibitors is currently u

10 -up tilt were significantly different on the midodrine and the placebo day: on the placebo day, 67% (

11 03 (2), ST-1059 (3, the active metabolite of midodrine), and phenylpropanolamine (4).

12 The combination of octreotide, midodrine, and albumin (triple therapy) is used to treat

13 available and generally fludrocortisone and midodrine are the drugs of first choice.

14 reflect underlying conditions, the need for midodrine before kidney transplantation is a risk marker

15 s developed neurally mediated syncope on the midodrine day (p < 0.02).

16 Midodrine decreased both supine and upright HR (all HR v

17 ine to 99+/-2 mm Hg at 2 hours, P<.001), and midodrine decreased supine systolic BP mildly.

18 or factors, as well as for the propensity of midodrine exposure, pretransplant midodrine use was inde

19 ogistic regression, including propensity for midodrine exposure.

20 concomitant vasoactive medications (3 in the midodrine group, 6 in the placebo group).

21 Midodrine hydrochloride, an alpha-agonist, could improve

22 Midodrine is efficacious and safe in the treatment of ne

23 Midodrine is prescribed to prevent symptomatic hypotensi

24 cy of active vasoactive drugs (terlipressin, midodrine, octreotide, noradrenaline, and dopamine; alon

25 ome; albumin; vasoconstrictor; terlipressin; midodrine; octreotide; noradrenaline; and norepinephrine

26 Finally, vasoconstrictor agents such as midodrine offer promise and remain the subject of clinic

27 They were randomized to a 10-mg dose of midodrine or placebo 3 times per day in a 6-week study,

28 The MID/OCT group received midodrine orally at an initial dose of 7.5 mg thrice dai

29 ine over placebo (4.17, 1.37-12.50) and over midodrine plus octreotide (10.00, 1.49-50.00) for this o

30 dence supported the use of terlipressin over midodrine plus octreotide (OR 26.25, 95% CI 3.07-224.21)

31 adrenaline with albumin are both superior to midodrine plus octreotide with albumin for reversal of h

32 evidence supported the use of noradrenaline, midodrine plus octreotide, and dopamine plus furosemide

33 2006 to 2008, of whom 308 (1.9%) had filled midodrine prescriptions in the year before transplantati

34 At 3 months, patients who used midodrine pretransplant had significantly (P < 0.05) hig

35 In the supine position, midodrine produced no significant change in blood pressu

36 In the evaluable patients, midodrine resulted in improvements in standing systolic

37 These results indicate that midodrine significantly improves orthostatic tolerance d

38 (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater alpha

39 e response of patients to the alpha1-agonist midodrine supports the hypothesis of partial dysautonomi

40 with the selective alpha1-adrenergic agonist midodrine, the inappropriate heat loss over their tail s

41 We hypothesized that midodrine use before kidney transplantation may be a nov

42 pensity of midodrine exposure, pretransplant midodrine use was independently associated with risks of

43 Adjusted associations of pretransplant midodrine use with complications at 3 and 12 months post

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。